Literature DB >> 33462759

Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review.

Adam J N Raymakers1,2,3, Kristina M Jenei4, Dean A Regier5,6,4, Michael M Burgess7, Stuart J Peacock5,6,8.   

Abstract

Year:  2021        PMID： 33462759     DOI： 10.1007/s40273-020-00995-3

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  1 in total

1.  Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.

Authors:  A Srikanthan; N Penner; K K W Chan; M Sabharwal; A Grill
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677
  1 in total
  2 in total

1.  Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.

Authors:  Jaclyn M Beca; Kelvin K W Chan; David M J Naimark; Petros Pechlivanoglou
Journal:  BMC Med Res Methodol       Date:  2021-12-18       Impact factor: 4.615

2.  Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada.

Authors:  Kristina Jenei; Stuart Peacock; Michael Burgess; Craig Mitton
Journal:  Curr Oncol       Date:  2021-07-17       Impact factor: 3.677
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.